Skip to content

Lexicon Pharmaceuticals LXRX Convertible Preferred Stock Issued Shares

Convertible Preferred Stock Issued Shares at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
0
Esperion Therapeutics logo
Esperion TherapeuticsESPR
0

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+273%
Enterprise value$976.73M+219%
P/S14.2×+5.7×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's convertible preferred stock issued shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's convertible preferred stock issued shares?
Lexicon Pharmaceuticals (LXRX) reported convertible preferred stock issued shares of 2.7M in Q1 2026.
How has Lexicon Pharmaceuticals's convertible preferred stock issued shares changed year-over-year?
Lexicon Pharmaceuticals's convertible preferred stock issued shares increased by 17.7% year-over-year, from 2.3M to 2.7M.
What does convertible preferred stock issued shares mean?
Number of convertible preferred shares that have been issued, whether held by investors or in treasury.